Synergistic Opioid Overdose Rescue Systems

Publication ID: 24-11857547_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Opioid Overdose Rescue Systems,” Published Technical Disclosure No. 24-11857547_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857547_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,547.

Summary of the Inventive Concept

Integrating opioid antagonist delivery with AI, IoT, blockchain, and novel materials to create more effective and personalized opioid overdose rescue systems

Background and Problem Solved

The original patent addressed the need for effective opioid overdose rescue, but its limitations include lack of personalized detection, delayed response, and limited therapeutic efficacy. The new inventive concept addresses these limitations by combining opioid antagonist delivery with advanced technologies to provide real-time detection, rapid response, and enhanced therapeutic outcomes

Detailed Description of the Inventive Concept

The new inventive concept comprises a system for opioid overdose rescue, integrating an opioid antagonist delivery device with an AI-powered sensor for detecting opioid exposure. The sensor triggers the delivery device to administer a therapeutically effective amount of the opioid antagonist. Additionally, the system may include a blockchain-based reward system to incentivize subjects to maintain abstinence from opioids, or a nanocarrier-based delivery system for targeted opioid receptor binding. The system may also incorporate an IoT-enabled tracking device for monitoring vital signs and an AI-powered predictive model for predicting opioid overdose risk

Novelty and Inventive Step

The new claims introduce the concept of integrating opioid antagonist delivery with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the synergistic combination of these technologies to create a more effective and personalized opioid overdose rescue system

Alternative Embodiments and Variations

Alternative embodiments may include using different AI algorithms, varying the type of IoT-enabled tracking device, or incorporating additional novel materials for enhanced therapeutic efficacy. Variations may also include adapting the system for use in different settings, such as emergency response or clinical treatment

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the opioid overdose rescue market, with potential applications in emergency response, clinical treatment, and public health initiatives. The target industries include pharmaceutical companies, medical device manufacturers, and healthcare providers

Field of Art

Pharmaceutical compositions, drug delivery systems, and medical intervention technologies with a focus on opioid antagonist formulations and overdose rescue methods

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or biomedical engineer with expertise in drug delivery, pharmacokinetics, medical device integration, and advanced therapeutic systems, holding at least a Master's degree with 3-5 years of specialized experience in pharmaceutical development

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies like AI, IoT, and blockchain with existing opioid antagonist delivery methods represents a predictable extension of known pharmaceutical and medical monitoring technologies. The core therapeutic mechanism of opioid antagonist delivery remains consistent with the source patent, while the proposed technological integrations represent incremental improvements in monitoring, delivery, and patient compliance. These variations demonstrate standard technological convergence strategies commonly employed in medical innovation.

Obvious Combinations & Variations

Source Patent Element
Parenteral formulation for nalmefene delivery with specific concentration and adjuvant parameters
PTD Variation
Nanocarrier-based delivery system targeting specific opioid receptors with integrated IoT tracking
Obviousness Reasoning
A PHOSITA would find it obvious to enhance drug delivery precision using known nanocarrier technologies, as targeted drug delivery represents a predictable optimization of existing pharmaceutical formulation techniques
Source Patent Element
Opioid antagonist composition for overdose rescue
PTD Variation
AI-powered sensor for detecting opioid exposure and automatically triggering antagonist delivery
Obviousness Reasoning
Integrating sensor technologies with pharmaceutical interventions is a known approach in medical device development, representing a logical extension of existing overdose rescue methodologies
Source Patent Element
Methods for treating opioid-related conditions
PTD Variation
Blockchain-based reward system to incentivize patient abstinence
Obviousness Reasoning
Behavioral modification techniques combined with pharmaceutical interventions are a predictable approach in addiction treatment, utilizing known motivational strategies to enhance therapeutic outcomes
Source Patent Element
Pharmaceutical compositions for opioid intervention
PTD Variation
AI-powered predictive model for assessing overdose risk using physiological monitoring
Obviousness Reasoning
Predictive risk assessment using physiological data represents a standard application of machine learning in medical monitoring, offering a foreseeable technological enhancement to existing intervention strategies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857547 and the published technical disclosure, a person of ordinary skill in the art would find the proposed technological variations obvious and predictable extensions of existing opioid antagonist delivery methods. The incremental technological integrations represent standard innovation strategies that do not rise to the level of non-obvious invention, thereby establishing robust prior art against potential future patent claims in this technological domain.

Original Patent Information

Patent NumberUS 11,857,547
TitleCompositions and methods for opioid antagonist delivery
Assignee(s)Purdue Pharma L.P.